Investors

2023

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2022

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2019

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd., has extended its original supply agreement (see RNS: 15 June 2017) with HLH BioPharma Vertriebs GmbH ("HLH") covering the supply of LP_LDL® capsules. The new agreement grants HLH: -

• An exclusive license to produce, package and commercialise a customised capsular product containing OptiBiotix's cholesterol reducing LP_LDL® strain in Germany with order volume commitments which double each year for the next three years to maintain exclusivity in this territory
• A nonexclusive license to produce, package and commercialise products containing OptiBiotix's cholesterol reducing LP_LDL® strain in Austria, Switzerland and the United Arab Emirates (UAE)
• The agreement is for three years from the data of signing
• The agreement restricts HLH from promoting and/or making sales, or exporting products outside these territories

HLH have over 20 years' experience in the distribution of probiotic and natural products under the brand names Lactobact® and is one of Europe's leading suppliers of probiotics to the pharmacy market.

This agreement recognises the successful launch of HLH in capsules containing LP_LDL® (RNS: 26 July 2017) under the brand name Lactobact® LDL-Control and promoting them directly to the pharmacy market in Germany and to consumers on their online platform. The commitment to double order volumes each year for the next three years to maintain exclusivity reflects the growing confidence from HLH in the science and effectiveness of LP_LDL®. This is another important step, in this case with an existing partner, in OptiBiotix's strategy of building the LP_LDL® brand, to serve multiple consumer healthcare and pharmaceutical markets around the world.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this extension of terms and territory with HLH who are one of Europe's leading suppliers of probiotics to the pharmacy market. The agreement recognises the success of HLH in building sales of its LP_LDL® containing Lactobact® brand in Germany and extends the terms and territory to support further sale growth. This is another step in extending the geographical reach of LP_LDL® as it builds recurring revenue streams and increases brand recognition, and the value of its products. This is part of a strategy which allows OptiBiotix to present customised product solutions through its partners to consumer health, pharmaceutical and retail companies around the world."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.